Summary of Cooper Companies Q1 2026 Earnings Call

1Key Financial Results and Metrics

Consolidated Revenue: $1.024 billion, up 6.2% year-over-year (2.9% organic growth).

CooperVision Revenue: $695 million, up 7.6% (3.3% organic growth).

CooperSurgical Revenue: $329 million, up 3.3% (2.2% organic growth).

Operating Margin: Improved significantly, with operating income up 13.9% to a 26.9% margin.

Non-GAAP EPS: Increased 20% to $1.10.

Free Cash Flow: Strong at $159 million, with capital expenditures of $102 million.

Debt: Net debt reduced to $2.4 billion; $92 million in stock repurchases during the quarter.

2Strategic Updates and Business Highlights

Market Share Gains: CooperVision gained market share for the 18th consecutive year, with strong performance in the Americas and EMEA regions.

Product Launches: Successful rollout of the MyDay daily silicone hydrogel portfolio and early adoption of MyDay MiSight in EMEA and Japan.

Operational Excellence: Organizational changes and IT implementations are yielding synergies, allowing for increased investment in sales and marketing while maintaining profitability.

Fertility Business: Positive trends noted in CooperSurgical’s fertility segment, with improving global genomics performance and new product launches.

3Forward Guidance and Outlook

Revenue Guidance: Consolidated revenues expected to be between $4.3 billion and $4.35 billion for fiscal 2026, reflecting organic growth of 4.5% to 5.5%.

Earnings Guidance: Raised to $4.58 to $4.66 per share, reflecting stronger operational performance.

Free Cash Flow Outlook: Increased to $600 million to $625 million for fiscal 2026, with expectations to generate over $2.2 billion in free cash flow through 2028.

4Bad News, Challenges, or Points of Concern

Asia Pacific Performance: Asia Pac region declined by 4%, primarily due to weakness in Japan linked to lower-margin hydrogel products. Expected to remain down in Q2 but anticipated recovery in Q3.

Middle East Uncertainty: Ongoing geopolitical issues may impact the fertility business, particularly in the Middle East, which accounts for about 2% of sales.

Competitive Pressures: Concerns regarding pricing dynamics and competition in the myopia control market, particularly with the introduction of Stellest.

5Notable Q&A Insights

Market Dynamics: Al White emphasized that the contact lens market is stabilizing, with expectations for improved growth driven by pricing and new product innovations.

Private Label Contracts: The company is seeing success in winning new contracts, particularly in MyDay-related products, which are expected to contribute positively in the latter half of the year.

Operational Efficiency: Significant improvements in operating expenses and margins were attributed to organizational restructuring and the adoption of AI technologies.

Fertility Market Recovery: There are signs of stabilization and improvement in the fertility market, with increasing IVF cycles noted in the U.S. and Europe, although challenges remain in Asia. Overall, Cooper Companies reported a strong start to fiscal 2026, with solid financial performance and strategic initiatives in place, despite facing challenges in specific regions and market segments.